| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 56 | 2025 | 1762 | 5.650 |
Why?
|
| Transcriptome | 32 | 2025 | 762 | 4.940 |
Why?
|
| Quantitative Trait Loci | 34 | 2025 | 630 | 3.110 |
Why?
|
| Multifactorial Inheritance | 16 | 2025 | 202 | 2.300 |
Why?
|
| Genetic Predisposition to Disease | 24 | 2024 | 2465 | 1.760 |
Why?
|
| Polymorphism, Single Nucleotide | 37 | 2025 | 2484 | 1.690 |
Why?
|
| Gene Expression Regulation | 13 | 2025 | 1985 | 1.300 |
Why?
|
| Models, Genetic | 11 | 2025 | 970 | 1.300 |
Why?
|
| Gene Expression | 12 | 2021 | 1301 | 1.280 |
Why?
|
| Computational Biology | 5 | 2025 | 578 | 1.080 |
Why?
|
| Genetic Variation | 16 | 2021 | 1415 | 0.990 |
Why?
|
| Genotype | 17 | 2025 | 1866 | 0.890 |
Why?
|
| Software | 5 | 2025 | 670 | 0.890 |
Why?
|
| Chromosome Mapping | 6 | 2021 | 1052 | 0.850 |
Why?
|
| Genomics | 8 | 2025 | 848 | 0.840 |
Why?
|
| Gene Expression Profiling | 12 | 2025 | 1518 | 0.820 |
Why?
|
| Schizophrenia | 3 | 2025 | 529 | 0.810 |
Why?
|
| Phenotype | 21 | 2025 | 2544 | 0.780 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 198 | 0.770 |
Why?
|
| RNA Splicing | 1 | 2024 | 157 | 0.750 |
Why?
|
| Organ Specificity | 6 | 2021 | 279 | 0.750 |
Why?
|
| Genetic Association Studies | 4 | 2022 | 300 | 0.750 |
Why?
|
| Asthma | 5 | 2023 | 1039 | 0.720 |
Why?
|
| Mental Disorders | 1 | 2025 | 455 | 0.650 |
Why?
|
| Humans | 83 | 2025 | 93515 | 0.650 |
Why?
|
| Proteome | 5 | 2025 | 153 | 0.620 |
Why?
|
| Brain | 3 | 2025 | 2391 | 0.600 |
Why?
|
| Age of Onset | 1 | 2019 | 342 | 0.550 |
Why?
|
| Alleles | 6 | 2021 | 1139 | 0.550 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2016 | 125 | 0.490 |
Why?
|
| Trans-Activators | 1 | 2019 | 439 | 0.490 |
Why?
|
| Genome, Human | 8 | 2020 | 823 | 0.470 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 3110 | 0.450 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 1117 | 0.440 |
Why?
|
| MicroRNAs | 7 | 2015 | 580 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2025 | 1229 | 0.420 |
Why?
|
| Cell Line, Tumor | 12 | 2015 | 2755 | 0.400 |
Why?
|
| Gene Frequency | 9 | 2023 | 700 | 0.390 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 754 | 0.370 |
Why?
|
| Privacy | 1 | 2012 | 20 | 0.360 |
Why?
|
| Genetic Loci | 3 | 2023 | 260 | 0.340 |
Why?
|
| Epigenesis, Genetic | 4 | 2025 | 555 | 0.340 |
Why?
|
| Rare Diseases | 2 | 2023 | 71 | 0.340 |
Why?
|
| Information Dissemination | 1 | 2012 | 124 | 0.340 |
Why?
|
| Cell Proliferation | 3 | 2015 | 1741 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2014 | 636 | 0.310 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 797 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 1338 | 0.290 |
Why?
|
| Bayes Theorem | 4 | 2023 | 402 | 0.290 |
Why?
|
| Case-Control Studies | 5 | 2020 | 1931 | 0.260 |
Why?
|
| Risk Factors | 7 | 2023 | 5899 | 0.250 |
Why?
|
| Female | 23 | 2025 | 48702 | 0.240 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 740 | 0.240 |
Why?
|
| HapMap Project | 7 | 2014 | 47 | 0.230 |
Why?
|
| Disease | 3 | 2021 | 92 | 0.230 |
Why?
|
| Linkage Disequilibrium | 4 | 2023 | 478 | 0.230 |
Why?
|
| Animals, Domestic | 1 | 2025 | 12 | 0.230 |
Why?
|
| Introns | 2 | 2024 | 300 | 0.220 |
Why?
|
| Ovarian Neoplasms | 4 | 2018 | 797 | 0.210 |
Why?
|
| Proteins | 3 | 2022 | 803 | 0.210 |
Why?
|
| Neoplasms | 3 | 2017 | 3169 | 0.210 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 409 | 0.210 |
Why?
|
| Neuroimaging | 1 | 2025 | 132 | 0.200 |
Why?
|
| Cisplatin | 4 | 2014 | 568 | 0.200 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 129 | 0.190 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 234 | 0.190 |
Why?
|
| Antineoplastic Agents | 5 | 2014 | 2303 | 0.190 |
Why?
|
| Platinum | 2 | 2014 | 67 | 0.190 |
Why?
|
| Sample Size | 3 | 2018 | 128 | 0.180 |
Why?
|
| Carboplatin | 3 | 2011 | 322 | 0.170 |
Why?
|
| Male | 14 | 2025 | 44557 | 0.170 |
Why?
|
| Population | 1 | 2021 | 36 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 2715 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 306 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 244 | 0.170 |
Why?
|
| Insulin | 2 | 2017 | 1185 | 0.170 |
Why?
|
| Genotyping Techniques | 3 | 2018 | 71 | 0.170 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 227 | 0.160 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2020 | 20 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 174 | 0.160 |
Why?
|
| Machine Learning | 1 | 2023 | 341 | 0.150 |
Why?
|
| Neuroblastoma | 2 | 2014 | 396 | 0.150 |
Why?
|
| Muscular Dystrophies | 1 | 2019 | 54 | 0.150 |
Why?
|
| Linear Models | 3 | 2020 | 413 | 0.150 |
Why?
|
| Genome | 2 | 2020 | 407 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2019 | 67 | 0.150 |
Why?
|
| Databases, Genetic | 3 | 2021 | 282 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2022 | 256 | 0.150 |
Why?
|
| Rats | 1 | 2025 | 4072 | 0.140 |
Why?
|
| Estrogen Receptor alpha | 2 | 2017 | 155 | 0.140 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 72 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2020 | 149 | 0.140 |
Why?
|
| Documentation | 1 | 2019 | 97 | 0.140 |
Why?
|
| Metabolome | 1 | 2019 | 62 | 0.140 |
Why?
|
| Forced Expiratory Volume | 2 | 2018 | 136 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2020 | 333 | 0.140 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 125 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 83 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2023 | 1118 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 293 | 0.140 |
Why?
|
| Haptoglobins | 1 | 2017 | 9 | 0.130 |
Why?
|
| Body Mass Index | 3 | 2019 | 811 | 0.130 |
Why?
|
| Genes | 2 | 2021 | 258 | 0.130 |
Why?
|
| Chromosomes, Bacterial | 1 | 2017 | 23 | 0.130 |
Why?
|
| Lung | 3 | 2022 | 1366 | 0.130 |
Why?
|
| Chromosome Segregation | 1 | 2017 | 35 | 0.130 |
Why?
|
| Ribonucleoproteins | 1 | 2017 | 36 | 0.130 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 75 | 0.130 |
Why?
|
| Menarche | 1 | 2017 | 30 | 0.130 |
Why?
|
| Puberty | 1 | 2017 | 54 | 0.130 |
Why?
|
| Bacillus subtilis | 1 | 2017 | 89 | 0.130 |
Why?
|
| Time Factors | 3 | 2014 | 5410 | 0.120 |
Why?
|
| Pharmacogenetics | 4 | 2014 | 456 | 0.120 |
Why?
|
| Fasting | 1 | 2017 | 163 | 0.120 |
Why?
|
| Models, Statistical | 3 | 2021 | 585 | 0.120 |
Why?
|
| Chromosomes, Human, X | 2 | 2020 | 57 | 0.120 |
Why?
|
| Alternative Splicing | 1 | 2017 | 219 | 0.120 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 192 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 255 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2018 | 283 | 0.120 |
Why?
|
| Animals | 8 | 2025 | 28155 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 366 | 0.110 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 9 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 304 | 0.110 |
Why?
|
| Child | 4 | 2022 | 7355 | 0.110 |
Why?
|
| Genetics, Population | 1 | 2018 | 439 | 0.110 |
Why?
|
| Nedocromil | 1 | 2014 | 6 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 156 | 0.110 |
Why?
|
| Apoptosis | 4 | 2014 | 1721 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2020 | 1691 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2017 | 379 | 0.110 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2016 | 121 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 83 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 537 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2014 | 52 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2014 | 479 | 0.100 |
Why?
|
| Genetic Pleiotropy | 1 | 2014 | 29 | 0.100 |
Why?
|
| Nicotine | 1 | 2016 | 208 | 0.100 |
Why?
|
| Systems Biology | 1 | 2014 | 47 | 0.100 |
Why?
|
| Simvastatin | 1 | 2014 | 106 | 0.100 |
Why?
|
| Leiomyoma | 1 | 2017 | 211 | 0.100 |
Why?
|
| Proteomics | 2 | 2014 | 264 | 0.100 |
Why?
|
| Caenorhabditis elegans | 1 | 2016 | 245 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2014 | 93 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 3476 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 61 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 277 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 37 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 122 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 246 | 0.090 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 306 | 0.090 |
Why?
|
| Cytarabine | 1 | 2013 | 216 | 0.090 |
Why?
|
| Cytosine | 1 | 2013 | 121 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 1775 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 152 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2013 | 170 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2013 | 663 | 0.090 |
Why?
|
| Cortactin | 1 | 2011 | 11 | 0.090 |
Why?
|
| Glutamates | 1 | 2011 | 84 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 185 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2014 | 217 | 0.090 |
Why?
|
| Metabolomics | 1 | 2012 | 98 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2014 | 756 | 0.090 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 878 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2014 | 826 | 0.090 |
Why?
|
| Membrane Transport Proteins | 1 | 2012 | 169 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2014 | 2026 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2013 | 315 | 0.080 |
Why?
|
| Guanine | 1 | 2011 | 194 | 0.080 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2010 | 20 | 0.080 |
Why?
|
| Cell Line | 5 | 2013 | 2464 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2012 | 208 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2015 | 867 | 0.080 |
Why?
|
| RNA Interference | 3 | 2020 | 379 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1264 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2012 | 524 | 0.080 |
Why?
|
| RNA, Small Interfering | 3 | 2020 | 555 | 0.080 |
Why?
|
| Spatial Behavior | 1 | 2009 | 20 | 0.080 |
Why?
|
| Survival Rate | 1 | 2013 | 1948 | 0.080 |
Why?
|
| Algorithms | 4 | 2025 | 1953 | 0.070 |
Why?
|
| Inflammation | 1 | 2014 | 1050 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 306 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 813 | 0.070 |
Why?
|
| Adult | 4 | 2022 | 27918 | 0.070 |
Why?
|
| Movement | 1 | 2009 | 304 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2009 | 337 | 0.060 |
Why?
|
| Obesity | 1 | 2014 | 1018 | 0.060 |
Why?
|
| Models, Biological | 2 | 2011 | 1768 | 0.060 |
Why?
|
| Middle Aged | 4 | 2019 | 27573 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 3054 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 826 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1061 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2009 | 390 | 0.060 |
Why?
|
| Aged | 3 | 2019 | 20434 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2022 | 917 | 0.060 |
Why?
|
| Likelihood Functions | 2 | 2020 | 256 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2018 | 579 | 0.060 |
Why?
|
| Exome | 2 | 2016 | 141 | 0.050 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 317 | 0.050 |
Why?
|
| Risk | 2 | 2019 | 657 | 0.050 |
Why?
|
| Europe | 2 | 2016 | 337 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1073 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 711 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 82 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2023 | 145 | 0.050 |
Why?
|
| United States | 3 | 2023 | 7622 | 0.050 |
Why?
|
| Nigeria | 2 | 2014 | 162 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2014 | 2562 | 0.050 |
Why?
|
| Coenzyme A | 1 | 2022 | 13 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 26 | 0.050 |
Why?
|
| Japan | 1 | 2022 | 299 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2023 | 2441 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2365 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 249 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 1906 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 208 | 0.040 |
Why?
|
| Human Genome Project | 1 | 2021 | 22 | 0.040 |
Why?
|
| Cells | 1 | 2020 | 30 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 166 | 0.040 |
Why?
|
| Prostate | 1 | 2023 | 416 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 876 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2014 | 9099 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 210 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 83 | 0.040 |
Why?
|
| Comorbidity | 1 | 2022 | 1007 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2019 | 211 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 524 | 0.040 |
Why?
|
| Military Personnel | 1 | 2020 | 104 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 312 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2018 | 73 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 78 | 0.030 |
Why?
|
| Prognosis | 2 | 2018 | 3911 | 0.030 |
Why?
|
| Finland | 1 | 2017 | 31 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 2017 | 32 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 962 | 0.030 |
Why?
|
| Protein Stability | 1 | 2017 | 103 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1105 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2020 | 443 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 61 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 119 | 0.030 |
Why?
|
| Cysteine | 1 | 2017 | 145 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 422 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 355 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 375 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 235 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 319 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2017 | 191 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 183 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2017 | 342 | 0.030 |
Why?
|
| Biomarkers | 2 | 2014 | 1910 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 589 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2017 | 520 | 0.030 |
Why?
|
| Fertility | 1 | 2016 | 119 | 0.030 |
Why?
|
| Argonaute Proteins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Receptors, Glucagon | 1 | 2015 | 11 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 10 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 896 | 0.030 |
Why?
|
| ras Proteins | 1 | 2016 | 132 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 30 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 4272 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 543 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 1133 | 0.030 |
Why?
|
| Locomotion | 1 | 2016 | 145 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2017 | 914 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2014 | 48 | 0.030 |
Why?
|
| Budesonide | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 397 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 646 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 8 | 0.030 |
Why?
|
| Smoking | 1 | 2018 | 648 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 199 | 0.030 |
Why?
|
| Plicamycin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 152 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 146 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2014 | 61 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 140 | 0.020 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2013 | 3 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 134 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 278 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 292 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 128 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2017 | 1353 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3435 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 85 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 296 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2013 | 66 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2013 | 99 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 179 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 254 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2012 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 201 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2019 | 808 | 0.020 |
Why?
|
| Mice | 2 | 2020 | 12269 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 98 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 298 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 494 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2011 | 75 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 90 | 0.020 |
Why?
|
| Capecitabine | 1 | 2012 | 97 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1170 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 696 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1161 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 213 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 450 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 985 | 0.020 |
Why?
|
| Deer | 1 | 2009 | 5 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2011 | 454 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2010 | 325 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 1210 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 416 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 526 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 572 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1103 | 0.020 |
Why?
|
| Cell Movement | 1 | 2010 | 809 | 0.020 |
Why?
|
| Ecosystem | 1 | 2009 | 396 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 3220 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 3829 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1395 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 9606 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2014 | 10164 | 0.010 |
Why?
|